Esperion Q3 total revenue $34M (+79% YoY); FDA PDUFA date March 31, 2024

Esperion Therapeutics, Inc.

2023-Q3 EPS reported -$1.53 revenue$84,084,000

Q3 total revenue $34.0M (+79% YoY); U.S. product revenue $20.3M (+45% YoY).
Net loss $41.3M ($0.37 per share) vs $55.1M ($0.81) in prior year.
FDA accepted sNDA for expanded CV risk reduction label; PDUFA date March 31, 2024.
Cash $114.8M at Sep 30 vs $166.9M at Dec 31; FY 2023 OpEx guidance $225-245M.
Presented CLEAR Outcomes analyses at ESC showing 20% reduction in total MACE.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Esperion Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $34.0 million, net income $41.3 million, EPS $0.37.

Period: the third quarter ended September 30, 2023
Revenue: $34.0 million
Net income: $41.3 million
EPS: $0.37
Result: reported results

Exact text from the filing

--- EX-99.1 (EX-99.1) --- Esperion Reports Third Quarter 2023 Financial Results – Q3 U.S. Net Product Revenue Grew 45% Y/Y to $20.3 Million; Q3 Total Revenue Grew 79% Y/Y to $34.0 Million – – Q3 Retail Prescription Equivalents Grew 33% Y/Y and 8% Q/Q, Demonstrating Sustained Momentum into 2H 2023 – – Received FDA Acceptance of Application for Expanded CV Risk

View on SEC.gov

Browse all earnings releases →

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-037180

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.